Biofouling during outfitting at South Korean shipyards drives high demand for Selektope® antifouling solution

21 February 2018 – As global water temperatures increase, global ‘biofouling hotspots’ in subtropical/tropical areas are intensifying, exposing newbuildings at the world’s major shipyards to greater risk of hard fouling during the outfitting process. The effects of intense hard fouling on idle newbuilds can have great impact on a newly applied hull coating and on a vessel’s performance in sea trials.

Philip Chaabane, CEO, I-TECH AB

In response to this problem, a new antifouling coating specifically targeting hard biofouling prevention during the outfitting period was brought to market by Danish marine coatings specialist Hempel in late 2017. GLOBIC 9500S includes the unique antifouling ingredient Selektope® as part of its ‘smart biocide package’ that delivers boosted static performance against hard fouling for ships with extended idle periods.

Philip Chaabane, CEO I-TECH AB, says: “Our product is boosting the performance of sophisticated antifouling systems under harsh fouling conditions, such as those experienced during outfitting at shipyards in South Korea. Selektope® is clearly adding value to the coatings products that the major coating manufacturers offer.”

Selektope® is an organic, non-metal compound that repels barnacle settlement on ships’ hulls by temporarily stimulating the barnacle larvae’s swimming behavior. It is characterized by high efficacy at extremely low concentrations (0.1% w/w), is ultra-low leaching and offer paint manufacturers the flexibility to boost copper-based paint formulations or replace copper completely. Due to the low concentration required, Selektope® does not compromise the chemical structure, color or other cooperative biocides of a marine coating.

This first-of-its-kind antifouling technology caught the attention of coatings suppliers in the early stages of its research and development. To-date, several products have been launched onto the market and the number of Selektope®-containing coatings being sold by different manufacturers is increasing year-on-year.

I-Tech AB, the Swedish biotechnology company behind the development of Selektope®, recently responded to strong market demand for the antifouling ingredient in South Korea by appointing KhaiEL as Selektope’s exclusive importer and agent. Under the new agreement, I-Tech will continue to manage sales of Selektope® in South Korea while KhaiEL will exclusively handle imports.

“We are delighted to be working with such a highly reputed company in KhaiEL to strengthen the supply of Selektope® to South Korea. This business relationship reflects the need to address increasing demand for our product in South Korea, particularly from the shipyards and many owners running risks of extended idling, whether during newbuilding or operations,” says Philip Chaabane.

“KhaiEL is very proud to partner with I-Tech to represent the highly innovative Selektope® technology in the Korean market,” says Paul Cho, Marketing Director KhaiEL.

South Korea is a key market for I-Tech. The company believes that coatings containing Selektope® play a vital role for shipyards located in biofouling hotspots with its barnacle-repellent technology.

About Selektope®
Selektope® introduces, for the first time, a pharmacological mode of action to combat barnacle settlement. By temporarily stimulating the octopamine receptor, the barnacle larvae’s swimming behavior is activated and the organisms are deterred from the hull. These ground-breaking discoveries enable unrivalled power at very low concentrations, yet within the limits of rigorous risk assessments. Selektope® is an organic, non-metal compound with efficacy proven at 0.1% w/w.

About I-Tech AB
I-Tech is a Gothenburg based bio-tech company with global reach, holding all IP and regulatory rights to the antifouling agent Selektope® (generic name, medetomidine). The company is privately held and is supported by Swedish Energy Association, the European Innovation Initiative Eco-Innovation and FP7 SeaFront. The company is a member of the Astra Zeneca BioVentureHub.

Contact Details
Philip Chaabane, CEO
Tel: +46 (0) 73 910 37 08